128 related articles for article (PubMed ID: 9516601)
21. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
[TBL] [Abstract][Full Text] [Related]
22. Dose-dense paclitaxel-containing adjuvant therapy for breast cancer.
Hudis CA
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):16-8. PubMed ID: 9516597
[TBL] [Abstract][Full Text] [Related]
23. Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin.
Préfontaine M; Donovan JT; Powell JL; Buley L
Gynecol Oncol; 1996 May; 61(2):249-52. PubMed ID: 8626142
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel in combination with fluorouracil for advanced solid tumors.
Burris HA
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):50-2. PubMed ID: 9364544
[TBL] [Abstract][Full Text] [Related]
25. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
26. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Nicholson BP; Paul DM; Hande KR; Shyr Y; Meshad M; Cohen A; Johnson DH
Clin Breast Cancer; 2000 Jul; 1(2):136-43; discussion 144. PubMed ID: 11899652
[TBL] [Abstract][Full Text] [Related]
28. UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
Lück HJ; Scholz U; Kühnle H; Dethling J
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):74-6. PubMed ID: 10442368
[TBL] [Abstract][Full Text] [Related]
29. [Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
Wilke H; Stahl M; Köster W; Vanhöfer U
Med Klin (Munich); 2000 Jun; 95 Suppl 1():3-8. PubMed ID: 10941246
[TBL] [Abstract][Full Text] [Related]
30. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
31. High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience.
Wils JA
J Infus Chemother; 1996; 6(3):145-8. PubMed ID: 9229327
[TBL] [Abstract][Full Text] [Related]
32. A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer.
Scholz U; Lück HJ; Canzler U; Robner D; Kühnle H
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):44-6. PubMed ID: 11098492
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
35. Advanced colorectal cancer: quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil.
Bogliolo G; Pannacciulli I; Desalvo L; Barsotti B; Lerza R; Mencoboni M; Arboscello E
Anticancer Res; 2000; 20(1B):501-4. PubMed ID: 10769713
[TBL] [Abstract][Full Text] [Related]
36. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Bishop JF; Dewar J; Toner GC; Tattersall MH; Olver IN; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):19-23. PubMed ID: 9144686
[TBL] [Abstract][Full Text] [Related]
39. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
40. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
